Irregular chemotherapy is more dangerous than cancer itself Over the past half century, human beings have made significant progress in the treatment of various types of cancer. Traditional surgery, radiotherapy and chemotherapy are the three pillars of cancer treatment in the world today. Objectively speaking, these three methods have played an undervalued role in alleviating the pain of cancer patients, relieving clinical symptoms and effectively extending life expectancy. In China, more than 1.6 million new cancer patients occur each year, and overall speaking more than half of them need chemotherapy. Chemotherapy is the cornerstone of tumor treatment, and reasonable chemotherapy regimen, appropriate drug dosage and sufficient chemotherapy cycles are crucial. At present, the phenomenon of non-standardized and unscientific chemotherapy for tumors is very common, and the non-standardized treatment causes patients to miss the best time for treatment and the best remission period. As a result, patients miss the best time for treatment and the best remission period, and the resulting health care burden and health risks are increasing. Irregular chemotherapy is mainly manifested in two aspects: one is “under-treatment” and the other is “over-treatment”. First, “under-treatment” is mainly manifested in patients who need chemotherapy after surgery, and it is common that the dosage and usage of chemotherapy are not standardized. For example, most patients need chemotherapy after surgery for breast cancer, colorectal cancer, etc. The purpose of chemotherapy is to prevent tumor recurrence and metastasis, and whether chemotherapy is standardized or not will directly affect the survival time of patients. Imagine, if the full amount of chemotherapy drugs should be used, but only 80% or even half of them are used; if 5 days of drugs should be used, but only 3 days are used; if 2~3 kinds of drugs should be used in combination, but only 1 kind is used, will the effect be good? Not only the effect is poor, but also it will cause tumor resistance and affect the subsequent chemotherapy. However, such risk is not visible in a short period of time, and often metastasis of other organs or tumor recurrence occurs within 2-3 years after the patient’s surgery, which should cause us to pay great attention to this situation. Secondly, “excessive” treatment is mainly manifested in some patients with tumor recurrence and metastasis, without considering the patients’ benefit and, in a word, the phenomenon that life does not stop and chemotherapy does not stop is common. Therefore, avoiding over- and under-treatment is the core of standardized chemotherapy. The consequences of non-standardized chemotherapy can be imagined, and the most obvious adverse consequences are three: first, poor efficacy, second, high toxic side effects, and third, increased economic and mental burdens of patients. It is not uncommon to ignore the toxic reactions of drugs and not to follow the dosage and dosing rules of combined drugs, especially when the work is carried out by non-specialist doctors. Tumor chemotherapy is developing continuously in the process of advancement, and after tens of years, the chemotherapy regimen is always in the process of adjustment, determination and adjustment, that is, the chemotherapy regimen for the same disease is different for different stages. In order to standardize tumor chemotherapy, it is not only necessary to check the diagnostic process, treatment process and evaluation process of tumor chemotherapy, but also to improve the scientific awareness of tumor chemotherapy and to strengthen and promote the business quality of medical and nursing personnel specialized in tumor.